3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Neuroendocrine
×
zimberelimab
×
Clear all
NCT07337447
2026-01-13
REWENEC 01
Hospices Civils de Lyon
Phase 2
Not yet recruiting
122 enrolled